Promising efficacy results in prostate (with enzalutamide) and triple negative breast cancer (with PARP inhibitor). I was hoping for more details on the Newsora Phase 2/3 prostate cancer partership, but not much was said. The triple negative breast cancer results to be presented/published in near future, now is Phase 2. Plans to expand ZEN-3694/PARP inhibitor into ovarian, HR+ breast and prostate cancers. Brief mention of plan for ZEN-3694 in triple combo with a Merck and a Pfizer drug, but no details provided. Also, ZEN-3694 planned for use in trial with checkpoint inhibitor sponsored by a federal group, but again little detail provided.

Lots of irons in the fire with potential partners to pay for future trial costs while Zenith receiving non-refundable ROFR payments, milestone payments and royalty payments. 

I remain hopeful and excited. Similar to Resverlogix, a lot of potential but lots of plans that may or may not follow through. Remaining patient and optimistic.

BDAZ